Latest Press Release
Our Approach
IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today’s precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. IDRx’s pipeline programs include small molecule tyrosine kinase inhibitors, IDRX-42 and IDRX-73, designed to inhibit key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). Founded in 2021, IDRx’s leadership team has extensive experience in drug development and collectively has been involved in the discovery, development, and commercialization of more than 10 approved drugs.
Our Pipeline
IDRX-42 and IDRX-73 are both small molecule tyrosine kinase inhibitors (TKIs) designed to inhibit the key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). IDRX-42 is designed to potently inhibit both the primary mutations that drive the progression of most cases of GIST, and also the secondary mutations that contribute to loss of response to treatment.
A phase 1 study of IDRX-42 has been initiated, and is currently enrolling patients in the US and Europe. More information is available here.
Our Team
Our team and founders have extensive experience in drug development, and collectively have been involved in the discovery, development and commercialization of more than 10 approved drugs.
Partners
Investors
